Cambridge, UK, 17 March 2021: CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation platform combines CN Bio’s in vitro 3D liver model, whose phenotype and functions mimic that in vivo, with a range of other organs to more accurately recapitulate the multi-organ and systemic effects observed in humans. Demonstrating a key milestone in the Company’s mission to develop the most complete human ‘body-on-a-chip’ in the…
Manufactured in dedicated clean-rooms with mandated changeovers before new production cycles - AMSBIO introduces new pHelper-Kan plasmid DNA optimized for Adeno-Associated Virus (AAV) manufacturing.Adeno-associated virus is a non-enveloped virus that can be engineered to efficiently deliver DNA sequences of interest into target cells with a low immunogenicity. Because of these unique characteristics, AAV-mediated genome editing has emerged as a highly promising gene delivery method.The robust virus packaging productivity of this pHelper-Kan plasmid has been tested in almost all AAV serotypes…
Glasgow, UK, 17 March 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round. The round was co-led by Forbion and Gilde Healthcare. Additional investors in this round include Novartis Venture Fund, and Eli Lilly and Company, joining existing investor BioMotiv and founding investor Advent Life Sciences. The proceeds will be used to accelerate the company’s growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to…
Research Triangle Park, NC, USA and Cambridge, UK, 17 March 2021 -- Inivata, a leader in liquid biopsy, will present new data on its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place on 10-15 April 2021. Data on the Company’s InVisionFirst-Lung liquid biopsy test will also be presented.
Two posters will highlight new data in support of RaDaR as a highly sensitive, personalized assay for the detection of residual disease and recurrence. The assay allows both detection of…
Cambridge 15th March 2021: Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to confirm Jo Parfrey as the new BBT Board Chair. Jo has been a non-executive director on the BBT Board for over four years and has chaired the company’s Audit Committee. She follows on from Dr Andy Richards who has formally stood down from the role after many years’ service. Dr Richards remains an active supporter of the Campus.Jo is a knowledgeable and successful investment…
Advent Life Sciences Becomes Latest Partner of One NucleusCambridge and London UK: 12th March 2021
Advent Life Sciences, one of the sector’s leading Trans-Atlantic venture investors has become the latest Partner to join One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
Shahzad Malik, General Partner, Advent Life Sciences commented ‘Advent is committed to investing in outstanding, early-stage science and to establish and nurture innovative companies in the UK, Europe and US. We greatly value partnerships in supporting…
Research Triangle Park, NC, USA and Cambridge, UK, 9 March 2021 -- Inivata, a leader in liquid biopsy, today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its RaDaR™ assay.
RaDaR is a personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity. The assay potentially allows detection of residual disease following initial treatment and early detection of relapse. RaDaR is built on Inivata’s proven InVision® liquid biopsy platform technology. This next-…
Cambridge, UK, Porto, Portugal, and London, UK – 08 March 2021: IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimisation of fully human antibodies, have announced that they have entered into an agreement with Quell Therapeutics Limited (Quell) regarding IONTAS / FJB’s proprietary libraries and technology platforms.
Quell is harnessing the suppressive capacity of Tregs to develop engineered Treg cell therapies to address several conditions of immune dysfunction. Under the terms of the agreement, IONTAS / FJB will provide Quell with a diverse panel…
AMSBIO announce a new HER2 control cell line array that was developed and is proven as an effective slide quality control for HER2 expression in breast cancer tissue samples.This new FFPE cell pellet microarray delivers a full dynamic range of HER2, ER and PR expression, validated by the Ventana system, to give immunohistochemical data in strong concordance with the routinely processed tissue sample.sections.Using cell line controls significantly lower the costs of immunohistochemical (IHC) examinations and fluorescence in situ hybridization (…